Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Issues Quarterly Earnings Results

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) announced its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.07) EPS for the quarter, Morningstar.com reports. Cumberland Pharmaceuticals had a negative return on equity of 0.13% and a negative net margin of 19.57%. The firm had revenue of $8.67 million during the quarter.

Shares of Cumberland Pharmaceuticals (NASDAQ:CPIX) opened at 6.90 on Friday. The company’s market cap is $109.68 million. Cumberland Pharmaceuticals has a 12 month low of $4.43 and a 12 month high of $7.49. The firm has a 50 day moving average price of $6.87 and a 200-day moving average price of $6.51.

ILLEGAL ACTIVITY NOTICE: “Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Issues Quarterly Earnings Results” was reported by Community Financial News and is owned by of Community Financial News. If you are reading this story on another publication, it was illegally stolen and reposted in violation of international copyright and trademark law. The correct version of this story can be viewed at https://www.com-unik.info/2017/08/19/cumberland-pharmaceuticals-inc-nasdaqcpix-issues-earnings-results-updated.html.

Several hedge funds have recently bought and sold shares of CPIX. Stonepine Capital Management LLC increased its stake in Cumberland Pharmaceuticals by 49.9% in the second quarter. Stonepine Capital Management LLC now owns 1,109,167 shares of the specialty pharmaceutical company’s stock worth $7,764,000 after buying an additional 369,250 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in Cumberland Pharmaceuticals by 0.3% in the second quarter. Dimensional Fund Advisors LP now owns 866,283 shares of the specialty pharmaceutical company’s stock worth $6,125,000 after buying an additional 2,464 shares in the last quarter. Vanguard Group Inc. increased its stake in Cumberland Pharmaceuticals by 0.4% in the second quarter. Vanguard Group Inc. now owns 298,635 shares of the specialty pharmaceutical company’s stock valued at $2,111,000 after buying an additional 1,180 shares in the last quarter. Renaissance Technologies LLC increased its stake in Cumberland Pharmaceuticals by 5.2% in the first quarter. Renaissance Technologies LLC now owns 270,240 shares of the specialty pharmaceutical company’s stock valued at $1,875,000 after buying an additional 13,240 shares in the last quarter. Finally, Acadian Asset Management LLC increased its stake in Cumberland Pharmaceuticals by 3.4% in the first quarter. Acadian Asset Management LLC now owns 130,430 shares of the specialty pharmaceutical company’s stock valued at $905,000 after buying an additional 4,257 shares in the last quarter. 34.50% of the stock is owned by institutional investors.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc (Cumberland) is a specialty pharmaceutical company. The Company is focused on the acquisition, development and commercialization of branded prescription products. The Company operates through specialty pharmaceutical products segment. The Company’s product portfolio includes Acetadote (acetylcysteine) Injection for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) Injection for the treatment of pain and fever; Kristalose (lactulose) for Oral Solution for the treatment of chronic and acute constipation; Omeclamox-Pak, (omeprazole, clarithromycin, amoxicillin) for the treatment of Helicobacter pylori (H.

Earnings History for Cumberland Pharmaceuticals (NASDAQ:CPIX)

What are top analysts saying about Cumberland Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Cumberland Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit